Skip to content

Trial · Interventional

RecruitingPhase 1Registry data

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

NCTNCT07224490 (opens ClinicalTrials.gov in a new tab)Other id565179Other idR37HD043341
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Recruiting
Phase
Phase 1
Enrollment
40 participants (estimated)
Sponsor
Stephanie B. Seminara, MD · Other
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

United States

Start
10 Mar 2026
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
First posted
4 Nov 2025
Last update posted
13 Jul 2026
Conditions
Reproductive Disorder · Neurodegeneration · SARS-CoV 2 · Long COVID

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202620272028202920302031
  1. Ph 1

    Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

    NCT07224490

    10 Mar 2026 to est. May 2030

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.

Interventions

  • Kisspeptin 112-121Drug

Arms1

  • Experimental

    Kisspeptin administration

    Single bolus of kisspeptin

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Difference in mean luteinizing hormone (LH) amplitude between cases and controls

    Time frame · Day of study visit (one to two hours)

    Registry description

    Difference between cases and controls of mean LH amplitude in response to kisspeptin

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 60 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria * Female (ages 18-45 years) or Male (ages 18-60 years) * No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration * For women, negative serum hCG pregnancy test * For cases, diagnosis of post-covid-19 syndrome * For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome Exclusion Criteria * Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol or the interpretation of results * Active use of illicit drugs (not including marijuana) * For women, * Pregnant * Trying to become pregnant during protocol participation * Breast feeding * Surgical or natural menopause

PepBank is a research reference. Talk to a doctor before you use any peptide.